Catalyst Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CATALYST PHARMS, and what generic alternatives to CATALYST PHARMS drugs are available?
CATALYST PHARMS has four approved drugs.
There are fourteen US patents protecting CATALYST PHARMS drugs.
There are one hundred and thirty-five patent family members on CATALYST PHARMS drugs in thirty-five countries and twenty-one supplementary protection certificates in fifteen countries.
Summary for Catalyst Pharms
| International Patents: | 135 |
| US Patents: | 14 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 4 |
Drugs and US Patents for Catalyst Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Catalyst Pharms | FYCOMPA | perampanel | SUSPENSION;ORAL | 208277-001 | Apr 29, 2016 | RX | Yes | Yes | 6,949,571 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Catalyst Pharms | AGAMREE | vamorolone | SUSPENSION;ORAL | 215239-001 | Oct 26, 2023 | RX | Yes | Yes | 11,382,922 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Catalyst Pharms | AGAMREE | vamorolone | SUSPENSION;ORAL | 215239-001 | Oct 26, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Catalyst Pharms | AGAMREE | vamorolone | SUSPENSION;ORAL | 215239-001 | Oct 26, 2023 | RX | Yes | Yes | 11,471,471 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Catalyst Pharms | FIRDAPSE | amifampridine phosphate | TABLET;ORAL | 208078-001 | Nov 28, 2018 | RX | Yes | Yes | 11,060,128 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Catalyst Pharms | FIRDAPSE | amifampridine phosphate | TABLET;ORAL | 208078-001 | Nov 28, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for CATALYST PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg | ➤ Subscribe | 2016-10-24 |
International Patents for Catalyst Pharms Drugs
Supplementary Protection Certificates for Catalyst Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1764361 | PA2013017 | Lithuania | ⤷ Sign Up | PRODUCT NAME: PERAMPANELUM; REGISTRATION NO/DATE: EU/1/12/776/001 - EU/1/12/776/016, 2012 07 23 EU/1/12/776/017 - EU1/12/776/023 20121029 |
| 1300396 | C01300396/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: PERAMPANEL; REGISTRATION NO/DATE: SWISSMEDIC 62440 14.12.2012 |
| 1300396 | 12C0074 | France | ⤷ Sign Up | PRODUCT NAME: PERAMPANEL, SEL DE CELUI-CI OU HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/12/776/001 20120723 |
| 1300396 | 420 | Finland | ⤷ Sign Up | |
| 1300396 | C300566 | Netherlands | ⤷ Sign Up | PRODUCT NAME: PERAMPANEL, EEN ZOUT OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/12/776/001 .... 016 20120723 |
| 1300396 | 132012902109980 | Italy | ⤷ Sign Up | PRODUCT NAME: PERAMPANEL(FYCOMPA); AUTHORISATION NUMBER(S) AND DATE(S): DA EU/1/12/776/001 A EU/1/12/776/016, 20120723 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
